venBio Partners
VC Fund
San Francisco, United States
venBio Partners is a VC fund in San Francisco focused on Biotechnology and Health Care. venBio invests in promising companies at various stages: from early to late stage, and from academic startups to spinouts. We tend to lead most of our investments, and we enjoy building syndicates and teams.We are mindful of potential acquisition partners from the outset, and we ensure that our companies are best positioned to meet theirrequirements. This includes IP, CMC, and the details of clinical trials, including indication, trial design, endpoints, powering, and regulatory considerations. Our team’s expertise and involvement helps companies make a bigger impact, and this leads to impactful and lasting relationships with the leaders that we work with.
- Total investments:
- 99
- Last investment:
- Lead investor:
- 42%
- Fund size:
- $550M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries venBio Partners invests in
Stages venBio Partners invests in
Countries venBio Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $20M–$81M
- Series B
- $39M–$190M
- Series C
- $36M–$259M
Investment Focus
Industry
- Biotechnology 53 (54%)
- Health Care 32 (32%)
- Pharmaceutical 25 (25%)
- Therapeutics 22 (22%)
- Medical 17 (17%)
Stage
- Series A 27 (27%)
- Series B 23 (23%)
- Series C 16 (16%)
- Post-IPO Equity 7 (7%)
- Series D 6 (6%)
Country
- United States 48 (48%)
- Canada 4 (4%)
- Switzerland 2 (2%)
- United Kingdom 2 (2%)
- China 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Behzad Aghazadeh
Managing Team
|
Managing Team | Total investments: 3 | Find email | |
Corey Goodman
Managing Partner
|
Managing Partner | Total investments: 20 | Find email | |
Richard Gaster
Managing Partner
|
Managing Partner | Total investments: 17 | Find email | |
Robert Adelman
Managing Partner
|
Managing Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines. | $32.5M / Series A / Jun 01, 2026 | ||
| Achieve Life Science manufactures pharmaceutical products. The firm develops cytisine as a smoking cessation aid. | $180M / Post-IPO Equity / Apr 16, 2026 | ||
| Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions. | $505M / Mar 02, 2026 | ||
| ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company.The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University.This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1. | $150M / Post-IPO Equity / Jan 30, 2026 | ||
| Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $305M / Series F / Jan 08, 2026 | ||
| Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease. | $200M / Venture - Series Unknown / Dec 17, 2025 | ||
| Aeovian Pharmaceuticals develops and investigates targeted small molecule therapeutics aimed at restoring cellular metabolic quality control to address dysregulated growth and signaling linked to certain rare genetic and age-related conditions. The company’s pipeline centers on compounds that selectively modulate specific biological pathways,including inhibitors designed to influence disease processes associated with neurological dysfunction. Its lead development candidate is a central nervous system-penetrant selective inhibitor being evaluated in clinical trials for refractory seizures related to a genetic disorder, and additional compounds are in earlier stages of investigation for other disease areas. Aeovian Pharmaceuticals also maintains a portfolio of proprietary molecules that engage defined molecular targets to explore potential treatments beyond its program. | $55M / Series B / Dec 16, 2025 | ||
| LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (singlegenemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline. | $40M / Post-IPO Equity / Jun 24, 2025 | ||
Attovia Therapeutics
|
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated. | $90M / Series C / Apr 15, 2025 | |
| Caldera was founded in 2025 to advance innovative biologics in IBD, assembling a senior leadership team with deep experience in the discovery and development of IBD therapeutics and a proven track record of building biotechnology companies through to successful exits.Caldera Therapeutics is a biotech company engaged in the development ofbispecific antibody CLD-423 for inflammatory bowel disease (IBD). | $75M / Series A / Apr 01, 2025 | ||
| See all 99 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does venBio Partners invest in?
venBio Partners invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 99 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does venBio Partners invest in?
venBio Partners typically joins rounds of $20M–$81M at Series A, $39M–$190M at Series B and $36M–$259M at Series C. These are whole funding-round sizes, not venBio Partners's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds venBio Partners took part in.
How do I contact venBio Partners?
Public channels for venBio Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at venBio Partners?
The team at venBio Partners includes Behzad Aghazadeh (Managing Team), Corey Goodman (Managing Partner) and Richard Gaster (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
